Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleReview
Open Access

S-PI-RADS and PI-RRADS for Biparametric MRI in the Detection of Prostate Cancer and Post-treatment Local Recurrence

MICHELE SCIALPI, EUGENIO MARTORANA, PIETRO SCIALPI, GIOVANNI BATTISTA SCALERA, EUGENIO BELATTI, MARIA CRISTINA AISA, ALFREDO D’ANDREA, FRANCESCO MARIA MANCIOLI, ALESSANDRO DI MARZO, FABIO TRIPPA and ALDO DI BLASI
Anticancer Research January 2023, 43 (1) 297-303; DOI: https://doi.org/10.21873/anticanres.16163
MICHELE SCIALPI
1Division of Diagnostic Imaging, Department of Medicine and Surgery, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michelescialpi1@gmail.com
EUGENIO MARTORANA
2Division of Urology, Nuovo Ospedale Civile Sassuolo, Modena, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PIETRO SCIALPI
3Division of Urology, Portogruaro Hospital, Venice, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIOVANNI BATTISTA SCALERA
1Division of Diagnostic Imaging, Department of Medicine and Surgery, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EUGENIO BELATTI
1Division of Diagnostic Imaging, Department of Medicine and Surgery, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA CRISTINA AISA
4Division of Obstetrics and Gynaecology, Department of Medicine and Surgery, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALFREDO D’ANDREA
5Division of Radiology, Ospedale di Caserta, Caserta, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCESCO MARIA MANCIOLI
6Division of Radiology, Ospedale Santa Maria, Terni, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALESSANDRO DI MARZO
7Radiation Oncology Centre, Ospedale Santa Maria, Terni, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FABIO TRIPPA
7Radiation Oncology Centre, Ospedale Santa Maria, Terni, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALDO DI BLASI
8Division of Radiology, Tivoli Hospital, Tivoli, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Corrigenda - March 01, 2023

Abstract

The application of biparametric magnetic resonance imaging (bpMRI) [T2-weighted (T2W) and diffusion weighted imaging (DWI)/apparent diffusion coefficient (ADC)] using dedicated structured methods, such as Simplified Prostate Imaging Reporting and Data System (S-PI-RADS) for the detection, categorization, and management of prostate cancer (PCa) is reported. Also, Prostate Imaging Reporting for Local Recurrence and Data System (PI-RRADS) for the detection and assessment of the probability of local recurrence after radiotherapy (RT) or radical prostatectomy (RP) in patients with biochemical recurrence (BCR) is proposed. Both S-PI-RADS and PI-RRADS assign to DWI/ADC a main role for the above purpose. S-PI-RADS identifies four categories and, on the basis of the qualitative and quantitative analysis of the restricted diffusion on ADC map and lesion volume, distinguishes two categories of lesions: category 3 (moderately homogeneous hypointense on ADC map) and category 4 (markedly homogeneous or inhomogeneous hypointense on ADC map). In category 3, two subcategories (3a: volume <0.5 cm3 and 3b: volume ≥0.5 cm3) suggesting clinical management. PI-RRADS distinguishes four assessment categories and suggests the stratification of the probability (ranging from very low for category 1 to very high for category 4) of local disease recurrence. In clinical practice, S-PI-RADS and PI-RRADS, based on bpMRI represent a potential valid approach that may facilitates the detection and management of PCa and for detecting local recurrence after treatment improving communication with other professionals.

Key Words:
  • Prostate cancer
  • recurrence
  • radiation therapy
  • radical prostatectomy
  • magnetic resonance imaging
  • simplified prostate magnetic resonance imaging for reporting (S-PI-RADS)
  • prostate magnetic resonance imaging for local recurrence reporting (PI-RRADS)
  • review

Numerous single-center and meta-analysis studies have found that overall prostate cancer (PCa) detection rates using biparametric magnetic resonance imaging (bpMRI) are equivalent to those of multiparameter MRI (mpMRI), with a comparable efficacy in guiding targeted biopsy (1–5). A narrative review from Prostate Imaging Reporting and Data System (PI-RADS) Committee, considering the high performance of bpMRI in detecting PCa, the short acquisition time, the reduced costs and the elimination of gadolinium-related risks, indicates it as a potential alternative to mpMRI, for meeting the increasing demand for MRI in the PCa diagnostic workup (6, 7).

Similarly to the diagnosis of PCa, bpMRI has a high performance in detecting local recurrences after treatment. After radiotherapy (RT), recurrence can occur at the primary tumor site or at a different site and can be detected as a focal high signal on DWI at high b-values, or focal moderate or marked low signal on apparent diffusion coefficient (ADC) maps. After completing RT, diffusion weighted imaging (DWI)/ADC can be immediately used as an alternative to dynamic contrast-enhanced (DCE). The latter, indeed, cannot be used earlier than three months because the prostate tissue develops an inflammatory reaction, which results in perfusion and blood volume increase (8). In addition, T2-weighted (T2W) and DWI achieve the highest diagnostic precision and inter-reader agreement in the detection of PCa after RT (9).

After radical prostatectomy (RP), the local tumor recurrence may specifically be detected in the prostatectomy bed as an area of restricted diffusion on DWI/ADC, unlike fibrosis, granulation tissue retained seminal vesicles, and residual glandular tissue which show no restriction diffusion on DWI/ADC. Despite the aforementioned potential in diagnosis and post-treatment of PCa, the lack of a dedicated reporting system for bpMRI does not allow its wide adoption in clinical practice. Undoubtedly, in the diagnosis of PCa, a dedicated bpMRI system cannot derive from PI-RADS v2.1, which considers the T2W and DWI as the dominant sequences for the transition zone (TZ) and peripheral zone (PZ), respectively. In PI-RADS v2.1, the DCE plays a secondary role in determining the PI-RADS 2.1 lesion category, by updating lesions from overall assessment category 3 to 4 in PZ based on positive DCE results. In addition, PI-RADS v2.1 does not define the management of score 3 or “equivocal” lesions and does not take into account quantitative measurements in order to increase the reproducibility of PI-RADS scores.

To strengthen the adoption of bpMRI in clinical practice and to facilitate the detection and localization of PCa and local recurrence after RT and RP, we propose dedicated reporting systems, S-PI-RADS and PI-RRADS, respectively, both based on bpMRI. For each system a quantitative analysis of the signal intensity (SI) of lesions based on a grayscale ADC map is suggested.

Biparametric Prostate MRI Protocol in Diagnosis and Post-treatment of Prostate Cancer

Prostate biparametric MRI at 3T without endorectal coil (ERC) and with a phased array body coil for the detection of PCa and the local recurrence of PCa workup includes: axial, sagittal, and coronal T2W, axial DWI using b-values of 0, 500, 1000 and 1500 s/mm2 and ADC map calculation, axial pelvic T1W fat-suppression, and T2-weighted SPIR MRI. MRI scanner at 1.5T with updated/optimal protocols would also produce good quality diagnostic images.

The prostate bpMRI protocol at 3T without ERC for diagnosis of PCa and detection of local recurrence after RT and RP is shown in Table I.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Prostate biparametric magnetic resonance imaging protocol: sequence parameters at 3T.

Steps for Biparametric MR Images Reading and Interpretation

To simplify and facilitate the use of S-PI-RADS and PI-RRADS, we recommend utilizing a 3-step approach which includes: 1) lesion detection and categorization, 2) prostate volume measurement and 3) lesion localization.

1) Lesion detection and categorization. In the detection of PCa, preliminary the axial T1-weighted fat-suppression images were analyzed to exclude hemorrhage post-biopsy foci. Next, four images (axial DWI with high b-value image, ADC map, sagittal and axial T2W images) are displayed on one or two 21.3-inch standard radiology high resolution 2 megapixel monitors and a contrast ratio of 1400:1. DWI at high b-values at 1500 s/mm2 (or inverted) and corresponding ADC maps were analyzed: a) for the detection PCa [both in peripheral zone and transition zone (TZ)] and for its categorization, and b) for detection and assessment of the probability of local recurrence in the irradiated prostate gland (PZ and TZ) and at level of the prostatectomy bed after RT and RP, respectively.

In patients suspicious of PCa, the lesion appears hyperintense on DWI at high b-values and moderate homogeneous or marked homogeneous or inhomogeneous hypointense on ADC maps. The lesions are categorized on ADC map as moderate homogeneous hypointensity (S-PI-RADS category 3) and marked homogeneous or inhomogeneous hypointensity (S-PI-RADS category 4). Moderately homogenous hypointense lesions on the ADC map are classified as S-PI-RADS category 3. These lesions were discriminated based on volume, calculated on DWI at high b-values with the ellipse formula (V=L×H×W×0.52) and in agreement with Epstein criteria (10), using a cut-off value of 0.5 cm3, in the S-PI-RADS category 3a [volume <0.5 cm3 (no biopsy)], and category S-PI-RADS 3b [volume ≥0.5 cm3 (targeted biopsy)]. Otherwise, targeted biopsy is indicated for all S-PI-RADS category 4. In a prostate with multiple lesions that show different restriction of diffusion, the “index lesion” should be considered the largest with marked restriction of diffusion or the smallest with marked restriction of diffusion compared to others that may be even larger but with moderate diffusion restriction.

After RP, the PCa recurrence appears as lobulated, curvilinear, or semi-circumferential, nodular-like, or plaque-like soft tissue thickening hyperintense on DWI at high b-values and moderately homogeneous or markedly homogeneous or inhomogeneous hypointense on ADC maps. DWI/ADC after RP allows detection of lesions suspected of local recurrence ≥5 mm (11).

After RT, the signal pattern of recurrence on DWI/ADC is similar to that of in situ primary PCa (12, 13); it appears as mass-like, focal rounded, lenticular or irregular.

After RT and RP, local recurrence appears as a lesion with SI moderately or markedly hypointense on ADC and classified as category 3 and 4, respectively.

In addition to qualitative analysis of lesions, for accurate PCa risk stratification by S-PI-RADS and categorization of 3 and 4 probability of local recurrence in PI-RRADS, and to improve inter-reader agreement, we proposed quantitative analysis of the SI of lesions using a grayscale ADC map.

We suggest the adoption of ADC quantitative analysis for measurable lesions. In particular, in S-PI-RADS, for differentiating lesions with volume <0.5 cm3 (S-PI-RADS category 3a vs. 4) and to indicate the follow-up for the subcategory 3a, while, in the PI-RRADS to distinguish probability categories (PI-RRADS category 3 vs. 4) and to monitor the treatment response. The grayscale ADC map for quantitative analysis of the SI of lesions in S-PI-RADS and PI-RRADS is reported in Figure 1.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Grayscale ADC map for quantitative analysis of the signal intensity (SI) of suspicious areas in S-PI-RADS and PI-RRADS. The apparent diffusion coefficient (ADC) scale measures the SI values of normal tissue and cell density of prostate cancer that increase with a decrease in ADC values. Three sub-parameters are identified: ADC minimum or ADCmin, ADC mean, and ADC maximum or ADCmax. ADCmax value is the water or urine (white) with high signal intensity value and is obtained from average of three circular regions-of-interest (ROIs) placed within the bladder; ADCmax value varies on the same MRI scanner and between different MRI scanners [for example on our 3T MRI unit (Achieva, Philips Medical Systems, Healthcare, Eindhoven, the Netherlands)] equipped with a phased array body coil, the ADCmax value on the ADC map generated using b-values of 0, 500, 1000 and 1500 s/mm2 can reach an average value of 4000]. ADCmin value is the bone (black) equal to 0 and is obtained from a circular ROI placed within the femur head; ADCmin value does not vary on the same MRI scanner nor between different MRI scanners. ADCmean is obtained from the formula: ADCmean=(ADCmax + ADCmin)/2. On grayscale ADC map, measurable and homogeneous areas with ADC values ≥ ADCmean can be considered as moderately hypointense SI areas on ADC map, while those with ADC values < ADCmean are considered as markedly hypointense SI areas on the ADC map.

2) Prostate volume measurement. In the detection of primary PCa and/or local recurrence after RT, the prostate volume is calculated on axial and sagittal T2W imaging using the ellipsoidal formula (V=L×H×W×0.52).

3) Lesion localization. In the detection of PCa and after RT, T2W imaging is able to localize the lesion detected on DWI/ADC and in the assessment of the prostate capsule involvement. In these patients, T2W imaging confirms the lesion detected on DWI/ADC: on T2W imaging PCa appears as a hypointense focus, and recurrence appears after RT local as a mass-like or focal moderate hypointensity compared to the irradiated prostatic tissue, in the site of the lesion detected on DWI/ADC. For lesion localization both in the detection of PCa and after RT, a prostate 41-sectors map is used (14).

On T2W the local recurrence after RP appears as a mass-like or focal lesion slightly hyperintense to the pelvic muscle in the site of the lesion detected on DWI/ADC and that occurs anywhere in the prostatectomy bed, but most commonly at the vesico-urethral anastomosis, the retro-vesical space, the bladder neck, near the seminal vesicles bed, or adjacent to the vas deferens (15, 16). Local recurrence after RP can be located exactly on T2W, using as landmarks, the vesico-urethral clock on the axial T2W and the distance of the lesion from the lower margin of the pubic symphysis on the sagittal T2W images.

S-PI-RADS and PI-RRADS Categories bpMRI-based

S-PI-RADS and PI-RRADS provide minimum acceptable technical standards for MR image acquisition and suggest a dedicated structured method for bpMRI reporting.

S-PI-RADS assesses four categories and indicates the management for each of them. Lesions with extra-prostatic extension (EPE) and/or invasion of the seminal vesicle are included in category 4 in addition to intraglandular lesions (17, 18).

S-PI-RADS categories based bpMRI are reported in Table II.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Simplified PI-RADS with biparametric magnetic resonance imaging.

PI-RRADS allows the detection of local recurrence after RP or RT in men with suspected BCR. Relapse after local therapy is defined by a rising PSA level >0.2 ng/ml following RP and >2 ng/ml above the nadir after RT (19, 20).

PI-RRADS includes four categories of bpMRI assessment of the likelihood of recurrence at the prostatectomy site after RP and in the prostate gland after RT. PI-RRADS assessment criteria, similarly to those of S-PI-RADS, are based firstly on DWI/ADC for lesion detection, size, and shape and then on anatomical T2W imaging for the lesion location in the prostatic bed after RP or intra-glandular site or extra-glandular extension after RT. PI-RRADS assessment categories and probability of recurrence are summarized in Table III.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

PI-RRADS with biparametric magnetic resonance imaging.

In the initial diagnostic approach for PCa workup, and in post-treatment, T2W spectral presaturation with inversion recovery sequence of the the entire pelvis, in addition to DWI, is useful in the detection of lymph nodes and bone metastases, and other findings.

Conclusion

In our experience, S-PI-RADS and PI-RRADS based on bpMRI can facilitate multidisciplinary cooperation and improve the detection and potential diagnosis of PCa and local prostate recurrence after RT and RP. Both systems will continue to develop and further studies are needed to validate them in clinical practice.

Acknowledgements

The Author thank Domenico Mezzasoma (Radiology Technician of the MRI Section, Santa Maria della Misericordia Hospital, Perugia, Italy) for his valuable contribution in verifying the MRI parameters acquisition.

Footnotes

  • Authors’ Contributions

    Conception and study design: MS, EM, GBS, FMM, FT, PS, ADB, supervision MS, EM, ADB; literature review: EB, AMC, ADM, writing: MS, EM, EB, AMC; critical review: MS, EM, FT, ADA, ADB. All Authors approved the final version of the manuscript.

  • Conflicts of Interest

    All Authors declare no conflicts of interest in relation to this study.

  • Received October 30, 2022.
  • Revision received November 14, 2022.
  • Accepted November 24, 2022.
  • Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Scialpi M,
    2. Prosperi E,
    3. D’Andrea A,
    4. Martorana E,
    5. Malaspina C,
    6. Palumbo B,
    7. Orlandi A,
    8. Falcone G,
    9. Milizia M,
    10. Mearini L,
    11. Aisa MC,
    12. Scialpi P,
    13. DE Dominicis C,
    14. Bianchi G and
    15. Sidoni A
    : Biparametric versus multiparametric MRI with non-endorectal coil at 3T in the detection and localization of prostate cancer. Anticancer Res 37(3): 1263-1271, 2017. PMID: 28314291. DOI: 10.21873/anticanres.11443
    OpenUrlAbstract/FREE Full Text
    1. Kuhl CK,
    2. Bruhn R,
    3. Krämer N,
    4. Nebelung S,
    5. Heidenreich A and
    6. Schrading S
    : Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology 285(2): 493-505, 2017. PMID: 28727544. DOI: 10.1148/radiol.2017170129
    OpenUrlCrossRefPubMed
    1. Woo S,
    2. Suh CH,
    3. Kim SY,
    4. Cho JY,
    5. Kim SH and
    6. Moon MH
    : Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 211(5): W226-W241, 2018. PMID: 30240296. DOI: 10.2214/AJR.18.19880
    OpenUrlCrossRefPubMed
    1. Niu XK,
    2. Chen XH,
    3. Chen ZF,
    4. Chen L,
    5. Li J and
    6. Peng T
    : Diagnostic performance of biparametric MRI for detection of prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 211(2): 369-378, 2018. PMID: 29894216. DOI: 10.2214/AJR.17.18946
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kang Z,
    2. Min X,
    3. Weinreb J,
    4. Li Q,
    5. Feng Z and
    6. Wang L
    : Abbreviated biparametric versus standard multiparametric MRI for diagnosis of prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 212(2): 357-365, 2019. PMID: 30512996. DOI: 10.2214/AJR.18.20103
    OpenUrlCrossRefPubMed
  3. ↵
    1. Schoots IG,
    2. Barentsz JO,
    3. Bittencourt LK,
    4. Haider MA,
    5. Macura KJ,
    6. Margolis DJA,
    7. Moore CM,
    8. Oto A,
    9. Panebianco V,
    10. Siddiqui MM,
    11. Tempany C,
    12. Turkbey B,
    13. Villeirs GM,
    14. Weinreb JC and
    15. Padhani AR
    : PI-RADS committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review. AJR Am J Roentgenol 216(1): 3-19, 2021. PMID: 32812795. DOI: 10.2214/AJR.20.24268
    OpenUrlCrossRefPubMed
  4. ↵
    1. Scialpi M,
    2. Martorana E,
    3. Scialpi P,
    4. D’Andrea A,
    5. Torre R,
    6. Di Blasi A and
    7. Signore S
    : Round table: arguments in supporting abbreviated or biparametric MRI of the prostate protocol. Abdom Radiol (NY) 45(12): 3974-3981, 2020. PMID: 32303773. DOI: 10.1007/s00261-020-02510-w
    OpenUrlCrossRefPubMed
  5. ↵
    1. Oppenheimer DC,
    2. Weinberg EP,
    3. Hollenberg GM and
    4. Meyers SP
    : Multiparametric magnetic resonance imaging of recurrent prostate cancer. J Clin Imaging Sci 6: 18, 2016. PMID: 27195184. DOI: 10.4103/2156-7514.181494
    OpenUrlCrossRefPubMed
  6. ↵
    1. Donati OF,
    2. Jung SI,
    3. Vargas HA,
    4. Gultekin DH,
    5. Zheng J,
    6. Moskowitz CS,
    7. Hricak H,
    8. Zelefsky MJ and
    9. Akin O
    : Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology 268(2): 440-450, 2013. PMID: 23481164. DOI: 10.1148/radiol.13122149
    OpenUrlCrossRefPubMed
  7. ↵
    1. Epstein JI,
    2. Walsh PC,
    3. Carmichael M and
    4. Brendler CB
    : Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5): 368-374, 1994. PMID: 7506797.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Aisa MC,
    2. Piscioli I,
    3. Di Blasi A and
    4. Scialpi M
    : PSA/biparametric MRI: An accurate potential diagnostic approach for detection and management of local recurrence after radical prostatectomy. Turk J Urol 46(1): 87-88, 2020. PMID: 31905126. DOI: 10.5152/tud.2019.19242
    OpenUrlCrossRefPubMed
  9. ↵
    1. Gaur S and
    2. Turkbey B
    : Prostate MR imaging for posttreatment evaluation and recurrence. Radiol Clin North Am 56(2): 263-275, 2018. PMID: 29420981. DOI: 10.1016/j.rcl.2017.10.008
    OpenUrlCrossRefPubMed
  10. ↵
    1. Mertan FV,
    2. Greer MD,
    3. Borofsky S,
    4. Kabakus IM,
    5. Merino MJ,
    6. Wood BJ,
    7. Pinto PA,
    8. Choyke PL and
    9. Turkbey B
    : Multiparametric magnetic resonance imaging of recurrent prostate cancer. Top Magn Reson Imaging 25(3): 139-147, 2016. PMID: 27187164. DOI: 10.1097/RMR.0000000000000088
    OpenUrlCrossRefPubMed
  11. ↵
    1. Scialpi M,
    2. Scialpi P,
    3. Pusiol T and
    4. D’andrea A
    : Biparametric MRI and 41 sector map for MRI/Transrectal ultrasound fusion biopsy to increase diagnostic accuracy of prostate cancer. Turk J Urol 44(6): 453-454, 2018. PMID: 31587700. DOI: 10.5152/tud.2018.04406
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hernandez D,
    2. Salas D,
    3. Giménez D,
    4. Buitrago P,
    5. Esquena S,
    6. Palou J,
    7. de la Torre P,
    8. Pernas J,
    9. Gich I,
    10. de Segura GG,
    11. Craven-Bartle J and
    12. Sancho G
    : Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy. Radiat Oncol 10: 262, 2015. PMID: 26704623. DOI: 10.1186/s13014-015-0574-6
    OpenUrlCrossRefPubMed
  13. ↵
    1. Poortmans P,
    2. Bossi A,
    3. Vandeputte K,
    4. Bosset M,
    5. Miralbell R,
    6. Maingon P,
    7. Boehmer D,
    8. Budiharto T,
    9. Symon Z,
    10. van den Bergh AC,
    11. Scrase C,
    12. Van Poppel H,
    13. Bolla M and EORTC Radiation Oncology Group
    : Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 84(2): 121-127, 2007. PMID: 17706307. DOI: 10.1016/j.radonc.2007.07.017
    OpenUrlCrossRefPubMed
  14. ↵
    1. Scialpi M,
    2. D’Andrea A,
    3. Martorana E,
    4. Malaspina CM,
    5. Aisa MC,
    6. Napoletano M,
    7. Orlandi E,
    8. Rondoni V,
    9. Scialpi P,
    10. Pacchiarini D,
    11. Palladino D,
    12. Dragone M,
    13. Di Renzo G,
    14. Simeone A,
    15. Bianchi G and
    16. Brunese L
    : Biparametric MRI of the prostate. Turk J Urol 43(4): 401-409, 2017. PMID: 29201499. DOI: 10.5152/tud.2017.06978
    OpenUrlCrossRefPubMed
  15. ↵
    1. Scialpi M,
    2. Aisa MC,
    3. D’Andrea A and
    4. Martorana E
    : Simplified prostate imaging reporting and data system for biparametric prostate MRI: a proposal. AJR Am J Roentgenol 211(2): 379-382, 2018. PMID: 29894218. DOI: 10.2214/AJR.17.19014
    OpenUrlCrossRefPubMed
  16. ↵
    1. Egevad L,
    2. Delahunt B,
    3. Srigley JR and
    4. Samaratunga H
    : International Society of Urological Pathology (ISUP) grading of prostate cancer – An ISUP consensus on contemporary grading. APMIS 124(6): 433-435, 2016. PMID: 27150257. DOI: 10.1111/apm.12533
    OpenUrlCrossRefPubMed
  17. ↵
    1. Cornford P,
    2. Bellmunt J,
    3. Bolla M,
    4. Briers E,
    5. De Santis M,
    6. Gross T,
    7. Henry AM,
    8. Joniau S,
    9. Lam TB,
    10. Mason MD,
    11. van der Poel HG,
    12. van der Kwast TH,
    13. Rouvière O,
    14. Wiegel T and
    15. Mottet N
    : EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4): 630-642, 2017. PMID: 27591931. DOI: 10.1016/j.eururo.2016.08.002
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 43 (1)
Anticancer Research
Vol. 43, Issue 1
January 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
S-PI-RADS and PI-RRADS for Biparametric MRI in the Detection of Prostate Cancer and Post-treatment Local Recurrence
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
S-PI-RADS and PI-RRADS for Biparametric MRI in the Detection of Prostate Cancer and Post-treatment Local Recurrence
MICHELE SCIALPI, EUGENIO MARTORANA, PIETRO SCIALPI, GIOVANNI BATTISTA SCALERA, EUGENIO BELATTI, MARIA CRISTINA AISA, ALFREDO D’ANDREA, FRANCESCO MARIA MANCIOLI, ALESSANDRO DI MARZO, FABIO TRIPPA, ALDO DI BLASI
Anticancer Research Jan 2023, 43 (1) 297-303; DOI: 10.21873/anticanres.16163

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
S-PI-RADS and PI-RRADS for Biparametric MRI in the Detection of Prostate Cancer and Post-treatment Local Recurrence
MICHELE SCIALPI, EUGENIO MARTORANA, PIETRO SCIALPI, GIOVANNI BATTISTA SCALERA, EUGENIO BELATTI, MARIA CRISTINA AISA, ALFREDO D’ANDREA, FRANCESCO MARIA MANCIOLI, ALESSANDRO DI MARZO, FABIO TRIPPA, ALDO DI BLASI
Anticancer Research Jan 2023, 43 (1) 297-303; DOI: 10.21873/anticanres.16163
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Biparametric Prostate MRI Protocol in Diagnosis and Post-treatment of Prostate Cancer
    • Steps for Biparametric MR Images Reading and Interpretation
    • S-PI-RADS and PI-RRADS Categories bpMRI-based
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Corrigenda
  • PubMed
  • Google Scholar

Cited By...

  • Biparametric MRI for Local Staging of Prostate Cancer: Current Status and Future Applications
  • Preoperative PI-RADS v2.1 Scoring System Improves Risk Classification in Patients Undergoing Radical Prostatectomy
  • Assessment of Prostate Volume and Prostate-specific Antigen Density With the Segmentation Method on Magnetic Resonance Imaging
  • Google Scholar

More in this TOC Section

  • Mobile and Wireless Technologies for Gastrointestinal Cancer Treatment
  • De Novo Testicular Cancers Arising After Renal Transplantation: A Narrative Review
  • Adjuvant Treatment for Resectable Pancreatic Cancer
Show more Review

Similar Articles

Keywords

  • Prostate cancer
  • recurrence
  • radiation therapy
  • radical prostatectomy
  • magnetic resonance imaging
  • simplified prostate magnetic resonance imaging for reporting (S-PI-RADS)
  • prostate magnetic resonance imaging for local recurrence reporting (PI-RRADS)
  • review
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire